Millions of Americans who take a common generic blood-pressure pill now face a supply disruption after the U.S. Food and Drug Administration posted a nationwide recall of Chlorthalidone Tablets, USP, 25 mg. The action, filed under Recall Number D-0610-2026, was triggered because the tablets failed dissolution specifications, meaning the pills did not release their active ingredient at the required rate during laboratory testing. The product is distributed by Rising Pharma Holdings, Inc., and the recall covers distribution across the entire United States.
Why a failed dissolving test pulled these pills off shelves
Dissolution testing measures how quickly and completely a tablet breaks down and releases its drug into the body. When a pill fails that test, it may deliver too little medication, too slowly, or unevenly. For a drug like chlorthalidone, which controls blood pressure over a full day, inconsistent release can leave patients exposed to dangerous spikes. The FDA classifies most dissolution-related recalls as Class II events, a designation reserved for situations where exposure could cause temporary or reversible health effects or where the probability of serious harm is remote but real.
That classification matters because it sits in a middle tier of urgency. Class I recalls cover products that could cause death or serious injury. Class III covers products unlikely to cause any health problem at all. A Class II designation signals that the FDA views the defective chlorthalidone tablets as a genuine clinical risk, not just a paperwork issue. Patients who have been taking affected tablets may have received inconsistent doses without knowing it, which can undermine blood-pressure control over days or weeks.
One pattern worth examining is whether recalls driven solely by dissolution failures take longer to move from initiation to public posting than recalls tied to contamination or incorrect potency. Dissolution problems are typically caught during routine stability testing rather than through adverse-event reports, and the testing and classification process can add time before the public sees an enforcement report. The FDA’s own recall database notes that entries appear once classified and may be updated over time, which means the gap between a company pulling product and the public learning about it can vary.
What federal records show about the chlorthalidone recall
The primary federal record for this action is Recall Number D-0610-2026, listed in the FDA’s Integrated Recall and Enforcement System. That entry identifies the product as Chlorthalidone Tablets, USP, 25 mg, names the reason as failed dissolution specifications, and confirms the recall is nationwide in scope. The event detail provides the specific recall event number that pharmacies and wholesalers use to trace affected inventory.
Labeling and packaging records maintained by the National Library of Medicine’s DailyMed database confirm that the product is distributed by Rising Pharma Holdings, Inc. Those records include the National Drug Code identifiers and label text that patients and pharmacists can cross-reference against the bottles on their shelves. Rising Pharma is a New Jersey-based generic drug company that distributes a range of off-patent medications. No public statement from the company explaining the root cause of the dissolution failure appears in the federal record or in the FDA’s press materials at the time of publication.
The recall applies specifically to the 25 mg strength. Chlorthalidone is a thiazide-like diuretic prescribed to lower blood pressure by reducing fluid volume in the body. It is one of the most widely used first-line treatments for hypertension and appears on multiple clinical guideline lists as a preferred generic option. A disruption in supply of even a single strength from one distributor can ripple through pharmacy networks, especially in regions where Rising Pharma’s version is the primary stocked generic.
For pharmacies, the recall means immediately identifying and quarantining any affected bottles, updating inventory systems, and notifying prescribers who frequently order chlorthalidone. Wholesalers may need to reallocate stock from other manufacturers to cover gaps, and some patients could experience short-term delays or be switched to a different generic version. Because chlorthalidone is often prescribed for long-term, stable blood-pressure control, even brief interruptions can be unsettling for patients who rely on a consistent daily routine.
Gaps in the public record and what patients should do next
Several pieces of information that patients and pharmacists need are still absent from the federal record. The enforcement report does not list the total number of bottles distributed before the recall or the specific lot numbers affected beyond the recall number itself. Without lot-level detail, individual patients cannot easily confirm whether their specific bottle is part of the recall without contacting their pharmacy directly. No adverse-event reports tied to this batch have surfaced in the primary sources, though that does not rule out unreported cases where patients experienced inadequate blood-pressure control.
The termination status of Recall D-0610-2026, which would indicate that the FDA considers the recall complete, is not yet reflected in the enforcement reports overview. That means the recall is still considered active and affected product may still be in the supply chain. Patients who take chlorthalidone 25 mg distributed by Rising Pharma should check their bottle’s label against the product identifiers in the DailyMed packaging record and contact their pharmacist to confirm whether their supply is affected.
Anyone currently taking a recalled bottle should not stop their medication abruptly, because sudden discontinuation of blood-pressure drugs can cause rebound hypertension. Instead, the practical first step is to call a pharmacist, confirm the product’s status, and request a replacement from an unaffected manufacturer or lot. If the pharmacy cannot immediately supply chlorthalidone, patients can ask their prescriber whether a temporary switch to another thiazide-type diuretic is appropriate and how to transition safely.
Patients should also monitor their blood pressure more closely during any switch. Home blood-pressure cuffs can help track readings in the days after changing to a new bottle or brand. Any sustained elevation, severe headache, chest pain, shortness of breath, or neurological symptoms such as weakness or slurred speech warrants urgent medical attention, regardless of recall status.
Pharmacists, meanwhile, can play a key role in translating the technical language of a Class II dissolution failure into practical advice. That includes explaining that the problem involves how the pill releases medication, not contamination with a foreign substance, and that the main concern is loss of blood-pressure control rather than acute poisoning. Clear counseling can reduce anxiety while reinforcing the importance of continuing some form of antihypertensive therapy without interruption.
As the FDA updates its enforcement records, more detail may emerge about the size and duration of this recall. Until then, patients who rely on chlorthalidone 25 mg should treat any unexpected change in pill appearance, pharmacy supply, or blood-pressure readings as a prompt to ask questions-not a reason to quietly stop treatment. In the context of a nationwide recall with incomplete public data, direct communication with pharmacists and clinicians remains the safest path to maintaining stable blood-pressure control.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
